



ESC Declaration of Interest Report

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in Guidelines development to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs are assessed prior to work commencing, and the ESC may decide to exclude any expert from a Guidelines activity based on the exclusion criteria as defined in the *ESC Declaration and Management of Conflict of Interest Policy, Annex 3*, as approved in July 2020.

The current policy and its annexes are available on the ESC website at www.escardio.org/DOI

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Adamo Marianna	2019 Nothing to be declared
	2020 Nothing to be declared
Baumbach Andreas	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Pharmacology - CERC : Research Organisation: Events Committees - Abbot Vascular : Stents - Microport : Stents - Sinomed : Stents Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Abbott Vascular : Intracoronary Imaging
	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Pharmacology - CERC : Research Organisation: Events Committees - Abbot Vascular : Stents - Microport : Stents - Sinomed : Stents

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Baumbach Andreas	2020 - Venus Medtech : Valves, CEP
Boehm Michael	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Abbott : Cardiology - Amgen : Cardiology - Astra Zeneca : Cardiology - Bayer : Cardiology - Boehringer-Ingelheim : Cardiology - Medtronic : Cardiology - Novartis : Cardiology - Servier : Cardiology - Vifor International : Cardiology - Bristol Myers Squibb : Cardiology <hr/> 2020 Financial Declaration - Abbott : Cardiology - Amgen : Cardiology - Astra Zeneca : Cardiology - Bayer : Cardiology - Boehringer-Ingelheim : Cardiology - Medtronic : Cardiology - Novartis : Cardiology - Servier : Cardiology

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Boehm Michael	2020 <ul style="list-style-type: none"> - Vifor International : Cardiology - Bristol Myers Squibb : Cardiology - Cytokinetics : Cardiology
Burri Haran	2019 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Medtronic : CIED - Biotronik : CIED <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Bayer : Cardiology - Medtronic : CIED <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Abbott : CIED - Boston Scientific : CIED - Medtronic : CIED - Biotronik : CIED <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member of the Swiss Working Group of Pacing and Electrophysiology

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Burri Haran	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boston Scientific : CIED consultancy - Abbott : CIED education - Medtronic : CIED education - Biotronik : CIED education <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Abbott : CIED - Boston Scientific : CIED - Medtronic : CIED - Biotronik : CIED
Butler Javed	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : Heart failure - Amgen : Heart failure - Astra Zeneca : Heart failure - Bayer : Heart failure - Janssen-Cilag : Heart failure - Sanofi Aventis : Heart failure - Vifor International : Heart failure - Relypsa : Heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry	
Butler Javed	2019	<ul style="list-style-type: none"> - Bristol Myers Squibb : Heart failure - CVRx : Heart failure - Boehringer Ingelheim : Heart failure - Adrenomed : Heart failure - Innolife : Heart failure - G3 Pharmaceutical : Heart failure - Array : Heart failure - V-Wave Limited : Heart failure
	2020	<p>Financial Declaration</p> <ul style="list-style-type: none"> - Abbott : Heart Failure - Astra Zeneca : Heart Failure - Janssen-Cilag : Heart Failure - Medtronic : Heart Failure - Novartis : Heart Failure - Pfizer : Heart Failure - Impulse Dynamics : Heart Failure - Vifor International : Heart Failure - Amgen Inc : Heart Failure - Bristol Myers Squibb : Heart Failure - Merck Sharp & Dohme : Heart Failure - Bayer AG : Heart Failure - Roche Diagnostics : Heart Failure - NovoNordisk : Heart Failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Butler Javed	<p>2020</p> <ul style="list-style-type: none"> - Cardiac Dimensions : Heart Failure - Boehringer Ingelheim : Heart Failure - Llvanova : Heart Failure - Adrenomed : Heart Failure - Innolife : Heart Failure - Applied Therapeutics : Heart Failure - G3 Pharmaceutical : Heart Failure - American Regent : Heart Failure - CVRx, : Heart Failure - Occulotech : Heart Failure
Celutkiene Jelena	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Pfizer : anticoagulation - Amgen : heart failure - Astra Zeneca : heart failure - Boehringer-Ingelheim : heart failure - Novartis : heart failure - Servier : heart failure - Sanofi Aventis : heart failure - Berlin Chemie AG : heart failure <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Novartis : digital health

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Celutkiene Jelena	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Pfizer : anticoagulation - Amgen : heart failure - Boehringer-Ingelheim : heart failure - Novartis : heart failure - Bayer Healthcare : heart failure - Astrazeneca : heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Roche Diagnostics : heart failure
Chioncel Ovidiu	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Advisory Board Heart Failure <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Servier : HF/ESC Congress 2019 <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Novartis : Heart Failure - Servier : Heart Failure - Vifor International : Heart Failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Chioncel Ovidiu	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Advisory Board Heart Failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Novartis : Heart Failure - Servier : Heart Failure - Vifor International : Heart Failure
Cleland John	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Philips : Cardiac Imaging - Amgen : Heart Failure - Astra Zeneca : heart failure - Medtronic : Heart Failure - Novartis : Heart Failure - Servier : Heart Failure - GlaxoSmithKline : heart failure - Johnson & Johnson : Heart Failure - Bayer Healthcare : Heart Failure - Torrent : heart failure - Vifor International : Heart Failure - Bristol Myers Squibb : heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Cleland John	<p>2019</p> <ul style="list-style-type: none"> - Respicardia : heart failure - Roche Diagnostics : Heart Failure - Zoll Medical : heart failure - Sensible Medical : Heart Failure - Stealthpeptides : Heart Failure - Corvedia : Heart Failure - Abbott : Heart failure devices and biomarkers - Actelion : Pulmonary Hypertension <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : CV Disease - Amgen : Heart Failure - Novartis : Heart failure - Philips : Heart Failure - Vifor International : Heart Failure - Bristol Myers Squibb : heart failure - Idorsia : Hypertension - Pharmacosmos : IV Iron - Pharmanord : Nutritional supplements <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bayer Healthcare : CV Disease - Amgen : Heart Failure - Boehringer-Ingelheim : Heart Failure - Novartis : Heart Failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Cleland John	<p>2019</p> <ul style="list-style-type: none"> - Philips : Heart Failure - Vifor International : Heart Failure - Roche Diagnostics : Heart Failure - MyoKardia : Heart Failure - Thermofisher : Heart Failure - Stealth Biopharmaceuticals : heart failure - Pharmacosmos : Heart Failure - Viscardia : Heart Failure - Devices <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - HEART FAILURE - Share options in HeartFelt technologies developing a device for measuring limb volume and congestion (CE marked; no trial data as yet). Share options in Viscardia developing a diaphragmatic pacing device (Phase IIa). Share options in PharmaIn developing developing new investigational medical products (Phase I) <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - European Society of Cardiology, British Society for Heart Failure, British Cardiovascular Society, Royal College of Physicians (London and Edinburgh), Royal College of Physicians and Surgeons (Glasgow), American College of Cardiology.
	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Philips : Cardiac Imaging - Amgen : Heart Failure - Astra Zeneca : heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Cleland John	<p>2020</p> <ul style="list-style-type: none"> - Medtronic : Heart Failure - Novartis : Heart Failure - Servier : Heart Failure - GlaxoSmithKline : heart failure - Johnson & Johnson : Heart Failure - Bayer Healthcare : Heart Failure - Torrent : heart failure - Vifor International : Heart Failure - Bristol Myers Squibb : heart failure - Respicardia : heart failure - Roche Diagnostics : Heart Failure - Zoll Medical : heart failure - Sensible Medical : Heart Failure - Stealthpeptides : Heart Failure - Corvedia : Heart Failure - Abbott : Heart failure devices and biomarkers - Actelion : Pulmonary Hypertension <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : CV Disease - Amgen : Heart Failure - Novartis : Heart failure - Philips : Heart Failure - Vifor International : Heart Failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Cleland John	<p>2020</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : heart failure - Medtronic : Heart failure devices - CVRx : Heart failure devices - Idorsia : Hypertension - Pharmacosmos : IV Iron - Pharmanord : Nutritional supplements <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bayer Healthcare : CV Disease - Amgen : Heart Failure - Boehringer-Ingelheim : Heart Failure - Novartis : Heart Failure - Philips : Heart Failure - Vifor International : Heart Failure - Roche Diagnostics : Heart Failure - MyoKardia : Heart Failure - Thermofisher : Heart Failure - Stealth Biopharmaceuticals : heart failure - Pharmacosmos : Heart Failure - Viscardia : Heart Failure - Devices <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> - Torrent : Development of an AGE breaker

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
<p>Cleland John</p>	<p>2020</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - HEART FAILURE - Share options in HeartFelt technologies developing a device for measuring limb volume and congestion (CE marked; no trial data as yet). Share options in Viscardia developing a diaphragmatic pacing device (Phase IIa). Share options in Pharmalyn developing new investigational medical products (Phase I) <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - I have helped support "Pumping Marvellous", a patient advocacy organisation based in the UK. I am a member of the British Society for Heart Failure.
<p>Coats Andrew</p>	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Faraday Australia : Acute MI - CVRx : Autonomic devices - ESN Cleer : Biomarkers - Actimed : Cancer - Bayer AG (event review committee member) : CV disease - CorVia : Device for HFpEF - Cardiac Dimensions : Devices for MR - Novartis : Heart Failure - Servier : Heart Failure - Menarini : Heart Failure - Astra Zeneca : Hyperkalaemia

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Coats Andrew	2019 <ul style="list-style-type: none"> - Vifor International : Iron deficiency - Arena : New drug development in acute heart failure - Nutricia : Nutrition - WL Gore : Prosthetic Valves - Respicardia : Sleep Apnoea
	2020 <p>Financial Declaration</p> <ul style="list-style-type: none"> - Faraday Australia : Acute MI - CVRx : Autonomic devices - ESN Cleer : Biomarkers - Actimed : Cancer - Bayer AG (event review committee member) : CV disease - CorVia : Device for HFpEF - Cardiac Dimensions : Devices for MR - Novartis : Heart Failure - Servier : Heart Failure - Menarini : Heart Failure - Astra Zeneca : Hyperkalaemia - Vifor International : Iron deficiency - Arena : New drug development in acute heart failure - Nutricia : Nutrition - WL Gore : Prosthetic Valves - Respicardia : Sleep Apnoea

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Crespo-Leiro Maria Generosa	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Heart Failure - Novartis : Heart Failure - Merck Sharp & Dohme : heart failure - Astellas : Heart Transplantation <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Novartis : heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Rovi : Heart Failure
	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Heart Failure - Novartis : Heart Failure - Vifor International : Heart Failure - Medtronic Foundation : Heart Failure - Rovi : Heart Failure - Astellas : Heart Transplantation <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Novartis : heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Crespo-Leiro Maria Generosa	<p>2020</p> <ul style="list-style-type: none"> - Astrazeneca : Heart Failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Rovi : Heart Failure
Farmakis Dimitrios T	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Atrial fibrillation, diabetes - Abbott Laboratories : Biomarkers - Roche Diagnostics : Biomarkers - Novartis : Heart failure - Orion Pharma : Heart failure <p>2020</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Bayer : Atrial fibrillation - Boehringer-Ingelheim : Atrial fibrillation, diabetes - Leo Pharma : Cancer - Orion Pharma : Heart failure
Gardner Roy Stuart	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulation - Boston Scientific : Cardiac Rhythm Management - Abbott Laboratories : Cardiac Rhythm Management

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Gardner Roy Stuart	<p>2019</p> <ul style="list-style-type: none"> - Novartis : Heart Failure - Webscape : Heart Failure interview - Vifor International : Heart failure therapies <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Heart failure preceptorships <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Vifor International : Sponsorship for HFA 2019 <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Abbott : CRM - Boston Scientific : CRM <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> - British Heart Foundation : Heart Failure (RHYTHM-HF) - I do NOT receive any of this grant as payment/salary <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - I work for the National Health Service (NHS), UK <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - I am the director of Professor Gardner Heart Failure Consultancy (HFC) Ltd where honoraria from 1A are paid I am the Chair Elect of the British Society for Heart Failure (BSH)

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Gardner Roy Stuart	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulation; empagliglozin - Boston Scientific : Cardiac Rhythm Management - Abbott Laboratories : Cardiac Rhythm Management - Astra Zeneca : Dapagliflozin - Novartis : Heart Failure - Webscape : Heart Failure interview - Servier : Heart failure therapies - Vifor International : Heart failure therapies <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Heart failure preceptorships - Novartis : Heart failure preceptorships <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Abbott : CRM - Boston Scientific : CRM <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> - British Heart Foundation : Heart Failure (RHYTHM-HF) - I do NOT receive any of this grant as payment/salary

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Gardner Roy Stuart	<p>2020</p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. - I work for the National Health Service (NHS), UK</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - I am the director of Professor Gardner Heart Failure Consultancy (HFC) Ltd where honoraria from 1A are paid I am the Chair Elect of the British Society for Heart Failure (BSH) I am on an endpoint committee for Myokardia 007</p>
Gilard Martine	<p>2019</p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. - Medtronic : French meetings - Bayer Healthcare : travel to ACC</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. - board of the French Society of Cardiology</p> <hr/> <p>2020</p> <p>Nothing to be declared</p>
Heymans Stephane	<p>2019</p> <p>Nothing to be declared</p> <hr/> <p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Cell Prothera : Advisory Board on clinical trial of cell therapy of myocardial infarction</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Heymans Stephane	<p>2020</p> <ul style="list-style-type: none"> - Astra Zeneca : Consultancy on preclinical and translational research in heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Pfizer : Amyloidosis
Hoes Arno	<p>2019</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Several : Multiple <p>2020</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Several : Multiple
Jaarsma Tiny	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure medication - Sensible Medical : monitoring device - Sensible : Telemonitoring device <p>2020</p> <p>Nothing to be declared</p>
Jankowska Ewa Anita	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : anticoagulants - Astra Zeneca : antiplatelets

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Jankowska Ewa Anita	<p>2019</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : diabetes and CVD - Novartis : Entresto - Abbott : FMR in heart failure - Cardiac Dimensions : heart failure devices - Servier : heart failure, ivabradine - Gedeon Richter : hiperlipidemia - Fresenius Nutrition : iv iron - Vifor International : IV iron - Berlin Chemie AG : lecanidipine, torasemide <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Vifor International : iv iron <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> - University of Zurich : heart failure - National Centre for Science (Poland) : iron metabolism, heart failure
	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : anticoagulants, vericiguat - Astra Zeneca : antiplatelets, dapagliflozine - Boehringer-Ingelheim : diabetes and CVD, empagliflozine - Sanofi Aventis : Fabry disease - Abbott : FMR in heart failure - Cardiac Dimensions : heart failure devices

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Jankowska Ewa Anita	<p>2020</p> <ul style="list-style-type: none"> - Vifor International : IV iron - Respicardia : phrenic nerve stimulation in CSA - Novartis : sacubitril/valsartan <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Vifor International : iv iron <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Payment from University of Zurich for lectures during the Postgraduate HF Course. Payment from NCBIR (Polish public entity) for research activities in the area of telemedicine in heart failure and non coding RNA
Lainscak Mitja	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Atrial fibrillation - Astra Zeneca : Heart failure - Novartis : Heart Failure - Vifor International : Heart Failure - Krka Pharma : Hypertension <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - OTHER - Actimed

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lainscak Mitja	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Anticoagulation - Boehringer-Ingelheim : Atrial fibrillation - Astra Zeneca : Heart failure - Novartis : Heart Failure - Vifor International : Heart Failure - Respicardia : Heart failure - Sanofi Aventis : Hyperlipidemia - Krka Pharma : Hypertension - Abbott Laboratories : Nutrition <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - OTHER - Actimed
Lam Carolyn Sp	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : Biomarkers - Roche Diagnostics : Biomarkers - Amgen : Heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lam Carolyn Sp	<p>2019</p> <ul style="list-style-type: none"> - Boston Scientific : Heart failure - Medtronic : Heart failure - Novartis : Heart failure - Merck Sharp & Dohme : Heart failure - Novo-Nordisk : Heart failure - MyoKardia : Heart failure - Stealth Biotherapeutics : Heart failure - CorVia : Heart failure - Janacare : Heart failure - Applied Therapeutics : Heart failure - Janssen Research & Development LLC : Heart failure - Biofourmis : Heart failure - Bayer : Heart failure, Cardiorenal initiative, Vascular protection - Menarini : Heart failure, Coronary artery disease - Boehringer Ingelheim : Heart failure, Diabetes - Astrazeneca : Heart failure, Diabetes, Real world evidence - Vifor Pharma : Heart failure, Iron deficiency - WebMD Global LLC : Medical education - Radcliffe Group Ltd : Medical education - Corpus. : Medical education <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Roche Diagnostics : Biomarkers - Bayer : Heart failure - Boston Scientific : Heart Failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lam Carolyn Sp	2019 <ul style="list-style-type: none"> - Astrazeneca : Heart failure, Real world evidence - Viifor Pharma : Intravenous iron - Medtronic : Renal denervation <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING - eKo.ai (co-founder and non-executive director)
	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Roche Diagnostics : Biomarkers - Actelion : Digital Health/Medical Technology - Darma Inc : Digital Health/Medical Technology - Us2.ai : Digital Health/Medical Technology - Amgen : Heart failure - Boston Scientific : Heart failure - Novartis : Heart failure - Sanofi Aventis : Heart Failure - Merck Sharp & Dohme : Heart failure - Novo-Nordisk : Heart failure - Cytokinetics : Heart Failure - Applied Therapeutics : Heart failure - Janssen Research & Development LLC : Heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lam Carolyn Sp	<p>2020</p> <ul style="list-style-type: none"> - Bayer : Heart failure, Cardiorenal initiative, Vascular protection - Boehringer Ingelheim : Heart failure, Diabetes - Astrazeneca : Heart failure, Diabetes, Real world evidence - Medscape : Medical Education - WebMD Global LLC : Medical education - Radcliffe Group Ltd : Medical education <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Roche Diagnostics : Biomarkers - Bayer : Heart failure - Boston Scientific : Heart Failure - Astrazeneca : Heart failure, Real world evidence <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING - Us2.ai (Co-founder and non-executive director)
Lyon Alexander	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Clinigen Group : Cardio-Oncology, Dexrazoxane - Roche Pharma : Cardio-Oncology, Herceptin, Perjeta - Takeda Pharmaceuticals : Cardio-Oncology, Multiple Myeloma, Ixazomib - Pfizer : Cardiotoxicity of cancer drugs for renal cancer and chronic myeloid leukaemia: sunitinib, axitinib, bosutinib - Novartis : Heart failure, Entresto, breast cancer - ribociclib

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lyon Alexander	<p>2019</p> <p>- Servier : Ivabradine, S44121, Pixantrone</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <p>- Healthcare - HEART FAILURE - Stock option (<1%) in Heartfelt Technologies Inc Stock option (1%) in Brainstorm Inc Stock option (1%) in Myocardial Solutions Inc</p>
	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>- Akcea : Cardiac Amyloidosis</p> <p>- Takeda Pharmaceuticals : Cardio-Oncology, Multiple Myeloma, Ixazomib</p> <p>- Pfizer : Cardiotoxicity of cancer drugs for renal cancer and chronic myeloid leukaemia: sunitinib, axitinib, bosutinib</p> <p>- GlaxoSmithKline : Heart Failure</p> <p>- Astra Zeneca : Heart Failure, Dapagliflozin</p> <p>- Novartis : Heart failure, Entresto, breast cancer - ribociclib, MPN</p> <p>- Ferring Pharmaceuticals : Prostate Cancer</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <p>- Healthcare - HEART FAILURE - Stock option (<1%) in Heartfelt Technologies Inc Stock option (1%) in Brainstorm Inc Stock option (1%) in Myocardial Solutions Inc</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
McDonagh Theresa	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : Heart Failure - Pfizer : Heart Failure - Vifor International : Iron Deficiency
	2020 Financial Declaration - Astra Zeneca : Heart Failure - Corpus : Heart Failure
McMurray John J V	2019 Financial Declaration Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Oxford University/Bayer : Acarbose (ACE trial Steering Committee and Glasgow University funding to run endpoint committee) - GSK : albiglutide (HARMONY Trial co-PI) and daprodustat (ASCEND-CKD Trial executive committee) - Novartis : aliskiren (AMOSPHERE Trial executive committee co-PI) - Abbvie (SONAR trial Steering Committee) : Atrasentan - Theracos : Bexagliflozin (BEST Trial executive committee - PI) - Pfizer (SPIRE trial DSMB) : Bococizumab - DalCor (DalGenE Steering Committee) : Dalcetrapib - Astra Zeneca (Executive committee/PI for Dapa-HF trial & co-principal for DELIVER & DETERMINE trials)) : dapagliflozin - GSK (ASCEND-CKD Phase III trials executive committee) : daprodustat vs conventional erythropoiesis stimulating agents - Cardurion : experimental PDE-9 inhibitor

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
McMurray John J V	<p>2019</p> <ul style="list-style-type: none"> - McMaster University (G-CHF registry steering committee) : global patient registry - BMS (STAND-UP AHF trial executive committee) : HNO donor (phase II trial) - Kidney Research UK (KRUK)/Kings College Hospital, London/Vifor-Fresenius Pharma - PIVOTAL trial steering committee and funding to Glasgow University to run the endpoint adjudication committee : iron sucrose - Novartis : My employer, Glasgow University, has been paid by Novartis (who manufacture sacubitril/valsartan) for my time spent as Executive Committee member for the trials listed (using sacubitril/valsartan and meetings related to these trial. Novartis has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/this drug. I am paid a standard clinical academic salary by the Scottish Funding Council through Glasgow University and my pay is not related to external funding/income. This principle applies to all the other trials/projects listed below. Sacubitril/valsartan (PARADIGM-HF co-PI, PARADISE-MI, PARAGON-HF co-PI, PERSPECTIVE and UK-HARP III Trial executive/steering committees, advisory boards, lectures) - Bayer (PANACHE Steering committee) : neladenoson bialanate (phase II trial) - Amgen Inc : omecamtiv mecarbil (COSMIC-HF and GALACTIC-HF Trial steering committees) - Resverlogix (payment to Glasgow University to run an Endpoint Committee for BETonMACE Phase III trial) : RVX000222 is an orally active Bromodomain Extra Terminal (BET) protein inhibitor (BETi) known to raise serum apolipoproteinA-I (apoA-I) via an epigenetic pathway that increases activity of the gene - Cardiorientis : ularitide (TRUE-AHF Trial executive committee/Glasgow University funded to run endpoint committee) - Merck Sharp & Dohme (VICTORIA trial DSMB) : vericiguat <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - British Heart Foundation : My Institute receives extensive funding as both a Centre of Research Excellence and for individual projects/programmes - this information is available of the institute website/in the annual reports https://www.gla.ac.uk/researchinstitutes/icams/ <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> - British Heart Foundation , Chief Scientist Office (Scottish Government), American Heart Association and NIH funding - see https://www.gla.ac.uk/researchinstitutes/icams/staff/johnmcmurray/#/grants : not product specific

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
McMurray John J V	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Global Clinical Trial Partners Ltd (GCTP) : Director - Abbott : Lecture fee - Astra Zeneca : lecture fee - Servier : lecture fee - Lupin : lecture fee - Hikma : lecture fee - Alkem Metabolics : lecture fee - Eris Lifesciences : lecture fee - Sun Pharmaceuticals : lecture fee - Medscape/Heart.Org : lecture fee - ProAdWise Communications : lecture fee - Radcliff Cardiology : lecture fee - The Corpus : lecture fee <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - AbbVie : My employer, Glasgow University, has been paid by Abbvie (who manufacture atrasentan) for my time spent as Steering Committee member for the SONAR trial (using atrasentan) and meetings related to this trial. Abbvie has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug. - Alnylam : My employer, Glasgow University, has been paid by Alnylam Pharmaceuticals for my participation in a company advisory board about development of ALN-AGT01.

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
McMurray John J V	<p>2020</p> <ul style="list-style-type: none"> - Amgen Inc : My employer, Glasgow University, has been paid by Amgen for my time spent as Steering Committee member for the mecarbil (COSMIC-HF and GALACTIC-HF Trial steering committees). These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/this drug. - Astrazeneca : My employer, Glasgow University, has been paid by AstraZeneca (who market dapagliflozin) for my time spent as Principal Investigator of DAPA-HF and Co-principal Investigator of DELIVER and DETERMINE (trials using dapagliflozin) in heart failure and meetings and other activities related to these trials. AstraZeneca has also paid my travel and accommodation for these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug. - Bayer : My employer, Glasgow University, has been paid by Bayer for my time spent as Steering Committee member for the PANACHE trial using neladenoson bialanate and for the FINEARTS trial with finerenone. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/drugs. - Bristol Myers Squibb : My employer, Glasgow University, has been paid by BMS for my time spent as a Steering Committee member for the STAND-UP clinical trial (using a HNO donor) in heart failure and meetings related to this trial. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug. - Boehringer-Ingelheim : My employer, Glasgow University, has been paid by Boehringer-Ingelheim for my advice about development of empagliflozin as a potential therapy for heart failure. - Cardurion : My employer, Glasgow University, has been paid by Cardurion for my participation in a company advisory board about development of a PDE 9 inhibitor in heart failure. - Cycleron : My employer, Glasgow University, has been paid by Cycleron for my advice about development of pralicigat as a potential therapy for heart failure. - Cytokinetics : My employer, Glasgow University, has been paid by Cytokinetics for my time spent as Steering Committee member for the ATOMIC-HF, COSMIC-HF and GALACTIC-HF trials and meetings and other activities related to these trials. Cytokinetics has also paid my travel and accommodation for some of these meetings/activities. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/this drug. - Dalcor : My employer, Glasgow University, has been paid by DalCor Pharmaceuticals for my time spent as Steering Committee member for the Dal-GenE trial and meetings/other activities related to this trial/treatment. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to this trial/this drug. - GlaxoSmithKline : My employer, Glasgow University, has been paid by GSK for my time spent as Co-principal investigator and Steering Committee member, respectively, for the Harmony-Outcomes trial (albiglutide) and two trials, ASCEND-D and ASCEND-ND, using daprodustat, and meetings related to these trials. GSK has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/drugs.

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
McMurray John J V	<p>2020</p> <ul style="list-style-type: none"> - Ionis : My employer, Glasgow University, has been paid by Ionis for my advice about development of ISIS757456 as a potential therapy for heart failure. - KBP Biosciences : My employer, Glasgow University, has been paid by KBP Biosciences for my advice about development of KBP-5074 as a potential therapy for heart failure. - Novartis : My employer, Glasgow University, has been paid by Novartis for my time spent as Executive Committee member and then co-principal investigator of ATMOSPHERE, co-principal investigator of the PARADIGM-HF and PARAGON-HF trials and Executive/Steering Committee member for PARADISE-MI, PERSPECTIVE and PARACHUTE-HF trials (with sacubitril/valsartan) and meetings/presentations related to these trials and aliskiren and sacubitril/valsartan. Novartis has also paid my travel and accommodation for some of these meetings. These payments were made through a Consultancy with Glasgow University and I have not received personal payments from Novartis in relation to these trials/drugs. - Servier : My employer, Glasgow University, has been paid by Servier for activities related to my role as Steering Committee member for the GALACTIC-HF trial. These payments were made through a Consultancy with Glasgow University and I have not received personal payments in relation to these trials/this drug. <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - British Heart Foundation : My Institute receives extensive funding as both a Centre of Research Excellence and for individual projects/programmes - this information is available of the institute website/in the annual reports https://www.gla.ac.uk/researchinstitutes/icams/ <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> - British Heart Foundation , Chief Scientist Office (Scottish Government), American Heart Association and NIH funding - see https://www.gla.ac.uk/researchinstitutes/icams/staff/johnmcmurray/#/grants : not product specific
Mebazaa Alexandre	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott Laboratories : biomarkers - Roche Diagnostics : biomarkers - Adrenomed : biomarkers, sepsis - Novartis : Heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Mebazaa Alexandre	2019 <ul style="list-style-type: none"> - Orion : Heart Failure - Servier : Heart Failure - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : Heart failure - Philips : ventilation <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - 4TEEN4 : Biomarker, heart failure - Adrenomed : biomarkers, sepsis
	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott Laboratories : biomarkers - Roche Diagnostics : biomarkers - 4TEEN4 : biomarkers - Adrenomed : biomarkers, sepsis - Novartis : Heart failure - Orion : Heart Failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - 4TEEN4 : Biomarker, heart failure - Roche Diagnostics : Biomarkers - Adrenomed : biomarkers, sepsis

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Metra Marco	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen as Executive Committee member of GALACTIC-HF trial : Heart failure - Servier as Executive Committee member of GALACTIC-HF trial : heart failure - Vifor International as Executive Committee member of DIAMOND and AFFIRM-HF trials : heart failure - Astra Zeneca for my participation to one advisory board : heart failure - Abbott Vascular for my participation to one advisory board : heart failure - Abbott Vascular speaker's fee : heart failure - Edwards Lifesciences speaker's fee : heart failure - Windtree Therapeutics for participation to one advisory board : heart failure <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Windtree therapeutics travel support to one advisory board : heart failure
	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Llvanova : Data Monitoring Committee member - Vifor Pharma : Executive committee member of DIAMOND-HF trial - Amgen : Member of the Executive committee of one trial, GALACTIC-HF - Astra-Zeneca : one advisory board fee

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2019</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - NICE (National Institute for Care Excellence) : £150 honoraria for attending guideline meetings over past 12 years as a patient representative. No future meetings envisaged. - James Lind Alliance, non-profit making initiative, http://www.jla.nihr.ac.uk/ : £150 honorarium, passed directly to Cardiomyopathy UK charity, 2019. No future meetings envisaged. <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - 1. I make monthly payments, by bank standing order, to Cardiomyopathy UK, a British charity which supports people with cardiomyopathy and with myocarditis. 2. I sit on the Patient Advisory Group of Brompton Hospital, London, advising on the applicability of research applications. 3. I am the patient representative on the English & Welsh National Heart Failure Audit. 4. I am the patient representative on the IRONMAN trial which is investigating the use of IV Iron in people with heart failure. 5. I am a contributor to a paper on patient experiences in a heart failure research trial (yet to be published/presented). <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Re item 7A: I have shares which are held inside and outside of a pension. I am unaware of what the shares are as they are all managed by a portfolio manager. Consequently I do not know whether I hold any shares in healthcare or healthcare-related companies, or in media or education companies.
	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Imperial College, London : 3 honoraria totalling GB£500/€550, passed in full to UK charity, CardiomyopathyUK. There will be no more honoraria.

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2020</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - I support actively the British charity CardiomyopathyUK and make a monthly payment to support their activities. I also passed the three honoraria in 2A to CardiomyopathyUK, in full.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Re item 7A: I have shares which are held inside and outside of a pension. I am unaware of what the shares are as they are all managed by a portfolio manager. Consequently I do not know whether I hold any shares in healthcare or healthcare-related companies, or in media or education companies.</p>
Muneretto Claudio	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Atricure : Atrial fibrillation</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. - Livanova : Heart valve</p> <hr/> <p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Atricure : Atrial fibrillation</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. - Livanova : Heart valve</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Speaker fee, consultancy - Novartis : speaker fee, consultancy - Servier : Speaker fee, consultancy Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - CHF Solutions : Aquapheresis Therapy in heart failure Travel and meeting support from healthcare industry, independent of the above activities. - Servier : ESC congress travel support
	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Servier : Speaker fee, consultancy - Boehringer Ingelheim : Speaker fee, consultancy Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - CHF Solutions : Aquapheresis Therapy in heart failure
Price Susanna	2019 Nothing to be declared

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Price Susanna	2020 Nothing to be declared
Rosano Giuseppe M C	2019 Financial Declaration Travel and meeting support from healthcare industry, independent of the above activities. - Vifor International : Heart Failure - Servier : Ischaemic heart disease - Menarini : Pharmacology <hr/> 2020 Financial Declaration Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Abbott Laboratories : Dyslipidaemia - Vifor International : Iron Deficiency - Menarini : Ischaemic heart disease / arterial hypertension - Astra Zeneca : speakers fees
Ruschitzka Frank	2019 Financial Declaration Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - IMC / AstraZeneca : Advisory Board - Radcliffe Group : Consulting service - Stiftung Pfizer Forschungspreis : Consulting service - Klub Class : Consulting service, Interview - Bayer : Grant to the University of Zurich: Postgraduate Course in Heart Failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Ruschitzka Frank	<p>2019</p> <ul style="list-style-type: none"> - Novartis : Grant to the University of Zurich: Postgraduate Course in Heart Failure - Servier : Grant to the University of Zurich: Postgraduate Course in Heart Failure - Abbott/St. Jude Medical : Grant to the University of Zurich: Postgraduate Course in Heart Failure - ESC : Secretarial and administrative support of the HFA Past-President 2019 - Amgen : Speaker Fee - Novartis : Speaker Fee - Servier : Speaker Fee - Boehringer Ingelheim : Speaker Fee - WebMD/Medscape : Speaker Fee - A+ Science AB / AstraZeneca : Speaker Fee - Brigham and Women's Hospital Boston : Speaker Fee - Fresenius Nutrition : Steering Committee Meetings <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Sanofi CH : ALIROL09100 - Hamilton Health : ARTESIA - Bayer : BAY 17938 & XATOA - Biotronik Berlin : BIOFLOW-IV & BIOFLOW-V - Biotronik : BIOVITESSE & CR021CHE001 - Insel BE : CEC 2017-01753-EVOPACS - Novartis : CLCZ696D2301 & CTQJ230A12001 - Swiss national foundation : CLEVER-ACS - Quintiles Sàrl : DSE-EDO-04-14 - Amgen : ECARA 20150245 & Study 20130296 - Fresenius GmbH DE : GENTLE-UF

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Ruschitzka Frank	2019 <ul style="list-style-type: none"> - Medtronic NL : MicraTM, Registry - Amgen : RNA Swiss Lipid Award - Swiss national foundation : Scylla and Charybdis - Aarhus Univ. DK : The_FAVOR_3 - Guidant Europe BE : UNTOUCHED - Novartis : VASCEND
	2020 <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen : Advisory Board - Stiftung Pfizer Forschungspreis : Consulting service - Astra Zeneca : Grant to the University of Zurich: Postgraduate Course in Heart Failure - Bayer : Grant to the University of Zurich: Postgraduate Course in Heart Failure - Novartis : Grant to the University of Zurich: Postgraduate Course in Heart Failure - Servier : Grant to the University of Zurich: Postgraduate Course in Heart Failure - Abbott/St. Jude Medical : Grant to the University of Zurich: Postgraduate Course in Heart Failure - ESC : Secretarial and administrative support of the HFA Past-President 2020 - Boehringer Ingelheim : Speaker Fee - Trama Solutions SL : Speaker Fee - IMC / AstraZeneca : Speaker Fee, Advisory Board <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Amgen : Aging Heart - Bayer : Aging Heart

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Ruschitzka Frank	<p>2020</p> <ul style="list-style-type: none"> - Vifor International : Aging Heart - MSD : Aging Heart - Boehringer Ingelheim : Aging Heart - Sanofi Aventis : ALIROL09100 - HAMILTON HEALTH SCIENCES : ARTESIA - Biotronic : BIOFLOW IV & BIOFLOW V - Biotronic : BIOVITESSE - Sahajanand IN / Cruz HBR : Cardiovascular European Research - Swiss national foundation : CLEVER-ACS - Biotronic : CR21CHE001 - Astrazeneca : DAPA-VOLVO - Quintiles : DSE-EDO-04-1-EU - Swiss national foundation : Effect of phosphodiesterase-5 inhibition - Amgen : HAYMANN Study 20130296, ECARA 20150245 - Novartis : HERITAGE CTQJ230A12001 - Medtronic : Micra TM Registry, EV ICD Pivotal - Boston Scientific : Multistars - Novartis : PARAGON CLCZ696D2301 - Kaneka Corporation : PMCF RAIDEN3 - Berlin Heart GmbH : Projekt Berlin Heart - V wave : Relieve-HF-Trial - SSS International Clinical Research : RHEIA - Amgen : RNA Swiss Lipid Award - Kantar GmbH : SANTORINI

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Ruschitzka Frank	<div> <div>2020</div> <div> <ul style="list-style-type: none"> - Swiss national foundation : Scylla and Charybdis - Abbott : Tako Tsubo - Guidant EUROPE NV : UNTOUCHED - Novartis : VASCEND - Bayer : XATOA, XATOC, BAY 17938 </div> </div>
Skibelund Anne Kathrine	<div> <div>2019</div> <div>Nothing to be declared</div> </div> <hr/> <div> <div>2020</div> <div>Nothing to be declared</div> </div>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer AG : Advisory board fees - Astra Zeneca : speaker fees - Boehringer-Ingelheim : speaker fees - Novartis : speaker fees
Abdelmassih Tony	<p>2020</p> <p>Nothing to be declared</p>
Abdullaev Timur	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Cardiology, Heart Failure - Polpharma : Cardiology, Heart Failure
Abid Leila	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novo-Nordisk : diabetes - Abbott : hypertension - Boehringer-Ingelheim : hypertension - Novartis : hypertension - Servier : hypertension

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Abid Leila	<p>2020</p> <ul style="list-style-type: none"> - Sanofi Aventis : hypertension - Menarini : hypertension <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : aprovasc - Novartis : exforge - Abbott : odrik
Aboyans Victor	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Antithrombotic therapies - Bristol Myers Squibb : Antithrombotic therapies - Astrazeneca : Diabetes <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bayer Healthcare : Peripheral Artery Disease
Adamopoulos Stamatis	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis (Honorarium for Chairmanship) : heart failure
Agathangelou Petros	<p>2020</p> <p>Nothing to be declared</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Altay Hakan	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Optimal Medical treatment in HF
Anker Stefan	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - BRAHMS GmbH : Biomarker in HF research - Abbott : COVID-19 SAB - Janssen / J&J : HF consultancy - Cordio : HF consultancy - Servier : HF registry steering committee - Boehringer-Ingelheim : HF trial executive committee (EMPEROR, EMPERIAL) - Vifor International : HF trial executive committees (AFFIRM-HF, DIAMOND-HF) - Cardiac Dimensions : HF trial steering committee - Bioventrix : HF trial steering committee - V-Wave : HF trial steering committee - Bayer AG : HF trial steering committee (DKD) - Astra Zeneca : SAB in HF (Germany) - Respicardia : Sleep apnea SAB. <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Vifor International : CHF therapy development, FAIR-HFpEF & Fair-HF2 - Abbott Vascular : CHF therapy development, RESHAPE-HF2

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Anker Stefan	<p>2020</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Fees for SAB-chair work (<10k EUR / yr) from Actimed Therapeutics, which is a research company (topic: cancer cachexia). I also hold founder's shares of Actimed Therapeutics (<20%).
Arbelo Elena	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Biosense Webster : Atrial fibrillation
Asteggiano Riccardo	<p>2020</p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979
Bajraktari Gani	<p>2020</p> <p>Nothing to be declared</p>
Bauersachs Johann	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Pfizer : Afib, Amyloidosis - Daiichi Sankyo : Afib, CAD - Boehringer-Ingelheim : Afib, Diabetes mellitus, Heart Failure - Bayer : Afib, heart failure - Bristol Myers Squibb : Afib, heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Bauersachs Johann	<p>2020</p> <ul style="list-style-type: none"> - Amgen : CAD, Heart Failure - Novartis : Heart Failure - Servier : Heart Failure - CVRx : Heart Failure - Cardior : Heart Failure - Vifor International : heart failure, hyperkalemia - Astrazeneca : heart failure, hyperkalemia <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Zoll Medical : Arrhythmia - Abiomed : cardiogenic shock - Vifor International : Heart failure - CVRx : Heart Failure
Bayes Genis Antonio	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : speaker fees, advisory board fees - Astra Zeneca : speaker fees, advisory board fees - Boehringer-Ingelheim : speaker fees, advisory board fees - Novartis : speaker fees, advisory board fees - Vifor International : speaker fees, advisory board fees - Roche Diagnostics : speaker fees, advisory board fees
Benlamin Hisham	<p>2020</p> <p>Nothing to be declared</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Bennis Ahmed	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Hear Failure - Astra Zeneca : Heart Failure - Boehringer-Ingelheim : Heart Failure - Sanofi Aventis : Hypertension - Merck Sharp & Dohme : Hypertension
Borger Michael A	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Cryolife : aortic surgery - Abbott : heart valve therapy - Edwards Lifesciences : heart valve therapy - Medtronic : heart valve therapy
Boskovic Aneta	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Atrial fibrillation
Bsata Walid	<p>2020</p> <p>Nothing to be declared</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Budts Werner	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Occlutech : PFO and ASD closure <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Occlutech : Interventional cardiology - St Jude Medical Abbott : Interventional cardiology - Medtronic : Venus valve
Cardoso Jose Carlos Magalhaes Silva	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Heart failure - Boehringer-Ingelheim : Heart failure - Novartis : Heart failure - Servier : Heart failure - Vifor International : Heart failure <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Vifor International : Heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Chrysohoou Christina	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Heart Failure - Pfizer : Heart Failure
Cikes Maja	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation - Pfizer : Anticoagulation, amyloidosis - Astra Zeneca : coronary heart disease - Astra Zeneca : Heart Failure - Boehringer-Ingelheim : Heart failure - Novartis : Heart failure - Orion : Heart failure - Teva Pharmaceutical Industries : Heart failure <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : heart failure - CorVia : Heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Abbott : Heart failure - Novartis : Heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Damman Kevin	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : Heart Failure - Boehringer-Ingelheim : Heart Failure - Vifor International : Heart Failure
Davies Ceri	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Heart failure
De Boer Rudolf	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Roche Diagnostics : Biomarkers - Abbott : heart failure device therapies - Astra Zeneca : heart failure pharmacotherapy - Bayer : heart failure pharmacotherapy - Novartis : heart failure pharmacotherapy <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : heart failure pharmacotherapy

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
De Boer Rudolf	<p>2020</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Abbott Laboratories : Biomarkers - Roche Diagnostics : Biomarkers - Astra Zeneca : heart failure pharmacotherapy - Boehringer-Ingelheim : heart failure pharmacotherapy - Novo-Nordisk : heart failure pharmacotherapy - Cardior Pharmaceuticals, GmbH : heart failure pharmacotherapy - Ionis Pharmaceuticals, Inc. : heart failure pharmacotherapy <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Membership of the American Heart Association (AHA), American College of Cardiology (ACC), and Dutch cardiac Society (NVVC)
De Pauw Michel	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Daichi Sankyo : anticoagulants - Actelion : Pulmonary Hypertension <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Actelion : Pulmonary Hypertension

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Medtronic : aortic stenosis (speaker fee in 2019 <1000 euro) - MSD : diabetes - speaker fee (800 euro) - GE Healthcare : echocardiography (<2000 euro) - Novartis : heart failure (speaker fee 800 euro) - Abbott Vascular : Mitral valve disease (<2000 euro) - Edwards Lifesciences : valvular heart disease (<2000 euro) <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - GE Healthcare : echocardiography - Edwards Lifesciences : tricuspid valve disease <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member of AHA, associate editor of Circulation and JASE
Dendale Paul	<p>2020</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Abbott : drugs - Astra Zeneca : drugs - Boehringer-Ingelheim : drugs - Novartis : drugs

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Dendale Paul	2020 <ul style="list-style-type: none"> - Sanofi Aventis : drugs - Vifor International : drugs - Bristol Myers Squibb : drugs - GE Healthcare : echo - Biosense : material - Medtronic : pm - Biotronik : PM
Dilaveris Polychronis E	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Digital solutions - Advisory board fees - Medtronic : Implantable loop recorders - speaker fees - Bayer : Non-Vitamin K Antagonist Anticoagulant - speaker fees
Drexel Heinz	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - European Society of Cardiology : Cardiology - Novartis : Clinical Lipidology - Austrian Pharmacy Association : Diabetes - Amgen : Lipids - Daiichi Sankyo : Lipids - Medscape : Lipids

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Ezekowitz Justin	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen : Heart failure - Bayer : Heart failure - Boehringer-Ingelheim : Heart failure - Novartis : Heart failure - Sanofi Aventis : Heart failure - Merck Sharp & Dohme : Heart failure - Astrazeneca : Heart failure - Cytokinetics : Heart failure - Applied Therapeutics : Heart failure - American Regent : Heart Failure <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - Cardiologist in health system
Falk Volkmar	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Berlin Heart : Advisory - Novartis : Consultancy - Abbott : Educational Grant for HCP's

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Falk Volkmar	2020 <ul style="list-style-type: none"> - Edwards Lifesciences : Educational Grant for HCP's - Medtronic : Educational Grant for HCP's - Cryolife / Jotec : Educational Grant for HCP's
Fauchier Laurent	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Healthcare - Boehringer-Ingelheim : Healthcare - Medtronic : Healthcare - Novartis : Healthcare - BMS/Pfizer : Healthcare - XO : Healthcare
Filippatos Gerasimos	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure - Servier : Heart Failure - Vifor International : Heart Failure - Boehringer-Ingelheim : Heart failure, Diabetes <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : CKD, Diabetes

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Filippatos Gerasimos	<p>2020</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Medtronic : Devices - Amgen : Heart Failure - Impulse Dynamics : Heart Failure - European Union : Heart Failure <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Vice President Onassis Cardiac Surgery Center Past Dean, University of Cyprus Medical School
Foscoli Marina	<p>2020</p> <p>Nothing to be declared</p>
Fras Zlatko	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : diabetes mellitus, anticoagulation - Amgen : lipid treatment - Sanofi Aventis : lipid treatment - Novartis : lipids, heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Novartis : lipidology - lipoprotein (a)

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Fraser Alan	<p>2020</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Biomedical Alliance in Europe, Chairman of Task Force on Regulatory Affairs and Medical Devices</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Scientific Coordinator of the CORE-MD consortium (EU Horizon 2020 project 965246, awarded to the ESC): project starts 1.4.2021</p>
Frey Norbert	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer Healthcare : anticoagulation</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Boehringer-Ingelheim : heart failure</p>
Gale Christopher Peter	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : acs hf</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Bristol Myers Squibb : af - Abbott : diabetes</p>
Gatzov Plamen Marinov	<p>2020</p> <p>Nothing to be declared</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Goncalvesova Eva	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen : heart failure - Boehringer-Ingelheim : heart failure - Novartis : heart failure - Merck : heart failure - Servier : heart failure, arterial hypertension - Medtronic : left ventricular assist devices - Johnson & Johnson : pulmonary hypertension - AOP Orphan Pharmaceuticals : pulmonary hypertension - Sandoz : Transplantation
Gotsman Israel	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Vifor International : Research
Gulati Geeta	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Speaker fees

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Gustafsson Finn	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : Heart Failure - Amgen : HF - Astra Zeneca : HF - Boehringer-Ingelheim : HF - Orion : HF - Pfizer : HF - Alnylam : HF - Pharmacosmos : HF - Inois : HF
Harris Julie	<p>2020</p> <p>Nothing to be declared</p>
Hayrapetyan Hamlet	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Servier : Arterial Hypertension, Coronary Heart Diseases - Egis Pharma : Arterial Hypertension, Coronary Heart Diseases - Novartis : Heart Failure <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Servier : ESC Congress

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Iacoviello Massimo	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : Cardiology
Ingimarsdottir Inga	2020 Nothing to be declared
Iung Bernard	2020 Nothing to be declared
Janssens Stefan	2020 Nothing to be declared
Jessup Mariell	2020 Other Positions of Influence Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - American Heart Association is a charity advocating for health.
Kamzola Ginta	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer : Anticoagulants/heart failure - Boehringer-Ingelheim : Diabetes and cardiovascular diseases/heart failure - Astra Zeneca : Heart Failure - Novartis : Heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Kamzola Ginta	2020 Other Positions of Influence Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Latvian Society of Cardiology
Kipiani Zviad V	2020 Nothing to be declared
Konradi Aleksandra	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : hypertension - Krka Pharma : hypertension - Gedeon Richter : hypertension - Servier : hypertension
Kotecha Dipak	2020 Financial Declaration Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer : Data Science (Advisory Board) - Amomed : Data Science (Advisory Board) - Protherics Medicines Development : Data Science (Advisory Board) Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Bayer : Funding for ESC STEEER-AF trial - Boston Scientific : Funding for ESC STEEER-AF trial - Daiichi Sankyo : Funding for ESC STEEER-AF trial

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p>2020</p> <ul style="list-style-type: none"> - Boehringer Ingelheim : Funding for ESC STEEER-AF trial - BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial - Amomed : Systematic review <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).
Krim Messaad	<p>2020</p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Servier : 2020 annual meeting of the French society of cardiology fees paiement
Kurlianskaya Alena	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Servier : speaker fees <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Servier : heart failure
Kusljugic Zumreta	<p>2020</p> <p>Nothing to be declared</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lambrinou Ekaterini	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : Heart Failure</p>
Lancellotti Patrizio	<p>2020</p> <p>Nothing to be declared</p>
Landmesser Ulf	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer AG : Advisory Board fee - Amgen : Speaker fee - Novartis : Speaker fee</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Novartis : Lipid Cardio Study - Bayer AG : Research Grant</p>
Lassus Johan Paul Eric	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer : Coronary artery disease, Heart Failure - Astra Zeneca : Heart Failure - Boehringer-Ingelheim : Heart Failure - Novartis : Heart failure</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lassus Johan Paul Eric	2020 <ul style="list-style-type: none"> - Vifor International : Heart failure - Roche Diagnostics : Heart failure - Pfizer : Oral anticoagulants
Leclercq Christophe	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Biotronik : device - Abbott : devices - Boston Scientific : devices - Medtronic : devices - Microport : devices
Lewis Basil S	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Vifor International : Heart failure - Kowa : Lipidology - CSL Behring : Lipidology, Secondary prevention <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Kowa : Lipidology

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Leyva Francisco	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : Device therapy - Medtronic : Device therapy - Microport : Device therapy
Lindmark Krister	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Heart Failure - Novartis : Heart Failure - Orion Pharma : Heart Failure - Vifor Pharma : Heart Failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Astra Zeneca : Heart Failure
Linhart Ales	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Servier : Arterial hypertension, coronary heart disease, heart failure - Boehringer-Ingelheim : Atrial fibrillation, diabetes - Sanofi Aventis : Fabry disease - Takeda Pharmaceuticals : Fabry disease

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lochen Maja-Lisa	2020 Nothing to be declared
Logeart Damien	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : heart failure - Boehringer-Ingelheim : heart failure - Novartis : heart failure - Bayer Healthcare : heart failure - Vifor International : heart failure Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Novartis : heart failure - Bayer Healthcare : heart failure
Logstrup Brian Bridal	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Heart Failure - speaker fee - Orion : heart failure - speaker fee
Lopatin Yury	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Boehringer-Ingelheim : empagliflozin

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lopatin Yury	2020 <ul style="list-style-type: none"> - Servier : Ivabradine, Trimetazidine - Novartis : sacubitril/valsartan - Merck Sharp & Dohme : Vericiguat
Lund Lars	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : Heart failure - Bayer : Heart Failure - Boehringer-Ingelheim : Heart failure - Novartis : Heart failure - Sanofi Aventis : Heart failure - Vifor International : Heart failure - Merck Sharp & Dohme : Heart failure - Medscape : Heart failure - Astrazeneca : Heart failure - Myocardia : Heart failure - Lexicon : Heart failure - Pharmacosmos : Heart failure - Radcliffe : Heart failure <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lund Lars	2020 Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Astra Zeneca : Heart failure - Boehringer-Ingelheim : Heart failure - Boston Scientific : Heart failure - Novartis : Heart failure - Vifor International : Heart failure
Lunegova Olga	2020 Nothing to be declared
Maeder Micha	2020 Nothing to be declared
Magdy Ahmed	2020 Nothing to be declared
Mancini Donna	2020 Financial Declaration Receipt of royalties for intellectual property. - Up to Date : medical writer on heart transplant, heart failure, mechanical support
Manintveld Olivier	2020 Nothing to be declared
Masip Josep	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Menarini : Consultancy - Orion : Speaker fee

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Masip Josep	2020 Travel and meeting support from healthcare industry, independent of the above activities. - Menarini : Echocardiography course
Melenovsky Vojtech	2020 Financial Declaration Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Regeneron/Sanofi : post-transplant vasculopathy and PCSK9 therapy
Milicic Davor	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novo-Nordisk : Antidiabetics - Alcaloid AD Skopje : Antihypertensive medications - PLIVA : Antihypertensive medications - Krka Pharma : Antihypertensives - Astra Zeneca : Antithrombotics in ACS - Novartis : ARNI - Roche Diagnostics : Biomarkers - Abbott : LVAD - Servier : Microvascular angina - Bayer : NOACs - Pfizer : NOACs - Boehringer-Ingelheim : NOACs, SGLT-2 inhibitors - Amgen : PCSK-9 inhibitors - Sanofi Aventis : PCSK-9 inhibitors

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Milicic Davor	<p>2020</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. - Abbott : Travel and hotel accomodation during the ESC Congress 2019 in Paris, France</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Croatian Heart Foundation, European Heart Network</p>
Moertl Deddo	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Heart failure - Boehringer-Ingelheim : Heart failure - Novartis : Heart failure - Vifor International : Heart failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. - Novartis : Heart failure - Merck Sharp & Dohme : Pulmonary hypertension</p>
Moore Alice May	<p>2020</p> <p>Nothing to be declared</p>
Mueller Christian Eugen	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer : Anticoagulants</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p>2020</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulants And Lipid lowering - Boehringer-Ingelheim : Antidiabetics - Astra Zeneca : Anti-Diabetics - Idorsia : Antiplatelet therapy - Roche Diagnostics : Diagnostics - Acon : Diagnostics - Osler : Diagnostics - Novartis : Heart Failure - Sanofi Aventis : Lipid lowering - Amgen : Lipid-lowering <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Novartis : Diagnostics - BRAHMS GmbH : Diagnostics - OrthoClinical Diagnostics : Diagnostics - Abbott Laboratories : Diagnostics - Roche Diagnostics : Diagnostics - Siemens : Diagnostics - Sphingotec : Diagnostics - quidel : Diagnostics - Upstream Medical Technologies : Diagnostics, Myocardial ischemia, BASEL VIII
Mustafayev Isakh	<p>2020</p> <p>Nothing to be declared</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Nef Holger	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : CAD - SMT Medical : CAD - Boston Scientific : Complex PCI - Shockwave medical : Complex PCI
Neubeck Lis	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Atrial fibrillation - Pfizer : Atrial fibrillation - Novo-Nordisk : CVD diabetes - Servier : Digital health
Nielsen Jens Cosedis	<p>2020</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - Member of Danish Heart Foundation <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - I received institutional research grants from the Novo Nordisk Foundation

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Noppe Stephanie	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : advisor board etude paragon
Noutsias Michel	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Pfizer : anticoagulation, heart failure - Bayer Healthcare : anticoagulation, heart failure - Astrazeneca : anticoagulation, heart failure - Novartis : heart failure - Fresenius : heart failure - Miltenyi Biotech : heart failure - Lifetech : Structural Heart Diseases - Zoll Medical : sudden cardiac death
O'Neill James	2020 Nothing to be declared
Petersen Steffen Erhard	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p>2020</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.) <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.
Petronio Anna Sonia	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boston Scientific : TAVI and mitral treatment - Abbott : TMVR <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Medtronic : TAVI
Ponikowski Piotr	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : anticoagulation - Vifor Pharma Ltd. : heart failure (HF) - Astra Zeneca : HF - Novartis : HF - Servier : HF

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Ponikowski Piotr	2020 - Boehringer Ingelheim : HF, anticoagulation
Prescott Eva	2020 Nothing to be declared
Rakisheva Amina	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer : Atrial Fibrillation - Novartis : Heart Failure
Richter Dimitrios	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : diabetes - Boehringer-Ingelheim : diabetes - Unipharm : hypertension-thrombosis - Amgen : lipids - Servier : LIPIDS - Sanofi Aventis : Lipids - Lilly : Lipids - Winmedica : lipids - Mylan : lipids - LaVIPHARM : lipids - ELPEN : LIPIDS-THROMBOSIS - Bayer Healthcare : Thrombosis

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Richter Dimitrios	<p>2020</p> <ul style="list-style-type: none"> - Leo Pharma : THROMBOSIS <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Bayer : THROMBOSIS - Sanofi Aventis : THROMBOSIS
Rimbasa Roxana	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Pfizer advisory board fee : ATTR-CM
Schulze Christian	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abiomed : Acute Heart Failure, Cardiogenic Shock - Berlin Chemie AG : General Cardiology - Bayer Healthcare : Heart Failure - Novartis : Heart Failure, Metabolism - Boehringer-Ingelheim : Heart Failure, Metabolism, Investigator-initiated study - Boston Scientific : Structural heart disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Boston Scientific : Structural heart disease

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Schulze Christian	<p>2020</p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. - I am employed as full professor of medicine with tenure at the University Hospital Jena and Friedrich-Schiller-University Jena, Germany.</p>
Seferovic Petar	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Heart failure - Boehringer-Ingelheim : Heart failure - Medtronic : Heart failure - Novartis : Heart failure - Servier : Heart failure - Respicardia : Heart failure</p>
Segovia Cubero Javier	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Abbott : VADs</p>
Senni Michele	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Abbott : CARDIOVASCULAR - Astra Zeneca : cardiovascular</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Senni Michele	2020 <ul style="list-style-type: none"> - Boehringer-Ingelheim : CARDIOVASCULAR - Novartis : cardiovascular - Vifor International : cardiovascular - Merck Sharp & Dohme : cardiovascular - Bayer AG : Cardiovascular
Sepp Robert	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : ARN inhibitors - Pharma Nord : coenzyme Q10 - Takeda Pharmaceuticals : Fabry disease - Astra Zeneca : SGLT2 inhibitors - Boehringer-Ingelheim : SGLT2 inhibitors
Shlyakhto Evgeny	2020 <p>Nothing to be declared</p>
Sitges Marta	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease - Medtronic : Heart Valve Disease <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Sitges Marta	<p>2020</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Heart Valve Disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Atrial Fibrillation - Menarini : Continuous Education on Cardiovascular Diseases - Novartis : Heart Failure - Merck Sharp & Dohme : Hypercholesterolemia <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - Speaker and consultant for Abbot.
Sousa Uva Miguel	<p>2020</p> <p>Nothing to be declared</p>
Srbinovska-Kostovska Elizabeta	<p>2020</p> <p>Nothing to be declared</p>
Stojkovic Sinisa	<p>2020</p> <p>Nothing to be declared</p>
Straburzynska-Migaj Ewa	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Pfizer : anticoagulation - Astra Zeneca : heart failure - Novartis : heart failure - Servier : heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Straburzynska-Migaj Ewa	<p>2020</p> <ul style="list-style-type: none"> - Vifor International : heart failure - Bayer : heart failure, stroke prevention - Boehringer-Ingelheim : stroke prevention, diabetes, heart failure <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : heart failure - Servier : heart failure <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - patient organisation - Polskie Stowarzyszenie Osób z Niewydolnością Serca
Tocchetti Carlo Gabriele	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen : Herat Failure, enrollment of patients in the Galactic trial <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Canadian Patent No. 2,613,477, issued on Dec 3, 2013 Inventors: Nazareno Paolocci, David A Kass, Carlo G Tocchetti. Owner: Johns Hopkins University Entitled: THIOL-SENSITIVE POSITIVE INOTROPES JHU Ref.: C04755-P04755-05 P75NTR ANTAGONISTS AND TREATMENT OF ACUTE AND CHRONIC CARDIAC DISEASE. Inventors: Paolocci; Nazareno; (Baltimore, MD) ; Feng; Ning; (Baltimore, MD) ; Tocchetti; Carlo G.; (Baltimore, MD) ; Takahashi; Cyrus; (Baltimore, MD) ; Carter; Bruce; (Nashville, TN). 2018. Source of the Document: United States Patent and Trademark Office Pre-Granted Publication. Patent number US20180271931, Publication date: Sep 27, 2018

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Touyz Rhian	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Consultancy-expert opinion
Tschoepe Carsten	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiology - Boehringer-Ingelheim : cardiology - Novartis : Cardiology - Orion : cardiology - Pfizer : cardiology - Impulse Dynamics : Cardiology - Bayer Healthcare : Cardiology - Avidal : Cardiology - Abiomed : Impella
Uuetoa Tiina	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : SGLT2- inhibitors in heart failure

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Uuetoa Tiina	<p>2020</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : SGLT2-inhibitors in heart failure</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Member of the working group by the Estonian Health Insurance Foundation in developing National Guidelines for Primary Care Physicians for the management of chronic heart failure (unpaid contribution) Co-Head of the National Heart Failure Nurse Curriculum Committee (unpaid contribution)</p>
Vataman Eleonora	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Egis Pharma : consultancy</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Nothing to declare</p>
Voronkov Leonid	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : Speakers fees</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Amgen : Consultancy</p>

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Voronkov Leonid	2020 Travel and meeting support from healthcare industry, independent of the above activities. - Krka Pharma : ESC Congress travel grant
Waltenberger Johannes	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Daiichi Sankyo : thrombosis Other Positions of Influence Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - German Heart Foundation (Deutsche Herzstiftung)
Zaliaduonyte Diana	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : speaker - Novartis : speaker

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer AG : Advisory board fees - Astra Zeneca : speaker fees - Boehringer-Ingelheim : speaker fees - Novartis : speaker fees
Aboyans Victor	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Antithrombotic therapies - Bristol Myers Squibb : Antithrombotic therapies - Astrazeneca : Diabetes <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bayer Healthcare : Peripheral Artery Disease
Antoniou Sotiris	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Pfizer : speaker fees for education - AF - Bayer AG : speaker fees for education - AF - Daiichi Sankyo : speaker fees for education -AF - Astra Zeneca : speaker fees for education - CVD

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Antoniou Sotiris	<p>2020</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Astra Zeneca : Joint working initiative on improving CV care</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Member of Arrhythmia alliance medical advisory panel</p>
Arbelo Elena	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Biosense Webster : Atrial fibrillation</p>
Asteggiano Riccardo	<p>2020</p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property. - Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979</p>
Baigent Colin	<p>2020</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Boehringer-Ingelheim : Cardiovascular and renal disease</p>
Baumbach Andreas	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Pharmacology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Baumbach Andreas	2020 <ul style="list-style-type: none"> - CERC : Research Organisation: Events Committees - Abbot Vascular : Stents - Microport : Stents - Sinomed : Stents - Venus Medtech : Valves, CEP
Borger Michael A	2020 <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Cryolife : aortic surgery - Abbott : heart valve therapy - Edwards Lifesciences : heart valve therapy - Medtronic : heart valve therapy
Celutkienė Jelena	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Pfizer : anticoagulation - Amgen : heart failure - Boehringer-Ingelheim : heart failure - Novartis : heart failure - Bayer Healthcare : heart failure - Astrazeneca : heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Roche Diagnostics : heart failure

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Cikes Maja	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation - Pfizer : Anticoagulation, amyloidosis - Astra Zeneca : coronary heart disease - Astra Zeneca : Heart Failure - Boehringer-Ingelheim : Heart failure - Novartis : Heart failure - Orion : Heart failure - Teva Pharmaceutical Industries : Heart failure <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : heart failure - CorVia : Heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Abbott : Heart failure - Novartis : Heart failure
Collet Jean-Philippe	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen : Lipids - Astra Zeneca : Post-PCI antiplatelet treatment

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p>2020</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Post-TAVR antithrombotic treatment <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Boston Scientific : Post-TAVR antithrombotic treatment - Bristol Myers Squibb : Post-TAVR antithrombotic treatment
Falk Volkmar	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Berlin Heart : Advisory - Novartis : Consultancy - Abbott : Educational Grant for HCP's - Edwards Lifesciences : Educational Grant for HCP's - Medtronic : Educational Grant for HCP's - Cryolife / Jotec : Educational Grant for HCP's
Fauchier Laurent	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Healthcare - Boehringer-Ingelheim : Healthcare - Medtronic : Healthcare - Novartis : Healthcare - BMS/Pfizer : Healthcare - XO : Healthcare

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : acs hf <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : af - Abbott : diabetes
Halvorsen Sigrun	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Anticoagulation - Sanofi Aventis : Lipidlowering <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation - Pfizer : Anticoagulation - Novartis : Heart failure
Iung Bernard	<p>2020</p> <p>Nothing to be declared</p>
Jaarsma Tiny	<p>2020</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Konradi Aleksandra	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : hypertension - Krka Pharma : hypertension - Gedeon Richter : hypertension - Servier : hypertension
Koskinas Konstantinos	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen : Cardiology - Daiichi Sankyo : Cardiology <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Cardiology
Kotecha Dipak	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Data Science (Advisory Board) - Amomed : Data Science (Advisory Board) - Protherics Medicines Development : Data Science (Advisory Board)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p>2020</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bayer : Funding for ESC STEEER-AF trial - Boston Scientific : Funding for ESC STEEER-AF trial - Daiichi Sankyo : Funding for ESC STEEER-AF trial - Boehringer Ingelheim : Funding for ESC STEEER-AF trial - BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial - Amomed : Systematic review <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).
Landmesser Ulf	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer AG : Advisory Board fee - Amgen : Speaker fee - Novartis : Speaker fee <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Novartis : Lipid Cardio Study - Bayer AG : Research Grant

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lewis Basil S	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Vifor International : Heart failure - Kowa : Lipidology - CSL Behring : Lipidology, Secondary prevention <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Kowa : Lipidology
Linhart Ales	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Servier : Arterial hypertension, coronary heart disease, heart failure - Boehringer-Ingelheim : Atrial fibrillation, diabetes - Sanofi Aventis : Fabry disease - Takeda Pharmaceuticals : Fabry disease
Lochen Maja-Lisa	<p>2020</p> <p>Nothing to be declared</p>
Neubeck Lis	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Atrial fibrillation

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Neubeck Lis	2020 <ul style="list-style-type: none"> - Pfizer : Atrial fibrillation - Novo-Nordisk : CVD diabetes - Servier : Digital health
Nielsen Jens Cosedis	2020 <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - Member of Danish Heart Foundation <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - I received institutional research grants from the Novo Nordisk Foundation
Petersen Steffen Erhard	2020 <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.) <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.
Prescott Eva	2020 <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Rakisheva Amina	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Atrial Fibrillation - Novartis : Heart Failure
Sitges Marta	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease - Medtronic : Heart Valve Disease <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Atrial Fibrillation - Menarini : Continuous Education on Cardiovascular Diseases - Novartis : Heart Failure - Merck Sharp & Dohme : Hypercholesterolemia

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Sitges Marta	<p>2020</p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. - Speaker and consultant for Abbot.</p>
Touyz Rhian	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : Consultancy-expert opinion</p>